In­dia is get­ting a man­u­fac­tur­ing boost that will add the ca­pac­i­ty to pro­duce an­oth­er 1 bil­lion in­jecta­bles.

Re­ci­pharm an­nounced the con­struc­tion of a new fill-fin­ish fa­cil­i­ty in Ut­tarak­hand, near Dehradun, in col­lab­o­ra­tion with the Sobti fam­i­ly. The de­vel­op­ment is the lat­est move in a part­ner­ship with the fam­i­ly, which be­gan in 2019 af­ter Re­ci­pharm in­vest­ed in Nichep­harm.

The site will up Re­ci­pharm’s ster­ile fill-fin­ish ser­vice to com­ple­ment al­ready ex­ist­ing lo­ca­tions in France, Ger­many and Italy. The project’s next step is to gain au­tho­riza­tion from Eu­ro­pean reg­u­la­tors.

“This is a great mile­stone for our on­go­ing part­ner­ship with the Sobti fam­i­ly,” Re­ci­pharm CEO Marc Funk said in a press re­lease. “From the new fa­cil­i­ty we’ll be able to pro­vide cus­tomers with in­valu­able ac­cess to high qual­i­ty ster­ile fill & fin­ish ca­pac­i­ty, which is in huge de­mand glob­al­ly. A lot of hard work has gone in to en­sur­ing the suc­cess of this project and we’re de­light­ed to see it come to fruition.”

The Sobti fam­i­ly, which is from In­dia, cre­at­ed Nichep­harm Life­sciences in 2019, and it will ini­tial­ly is­sue an 8% eq­ui­ty stake to Re­ci­pharm for an in­vest­ment of near­ly $10.45 mil­lion. Re­ci­pharm has the op­tion to ac­quire an ad­di­tion­al 16% share in Nichep­harm this year.

Ear­li­er in Ju­ly, Re­ci­pharm an­nounced the Mo­roc­can gov­ern­ment would pay $500 mil­lion to es­tab­lish a fill-fin­ish fac­to­ry over the next five years that is pri­mar­i­ly ded­i­cat­ed to man­u­fac­tur­ing African vac­cines. That will be up-and-run­ning by 2023, so long as it stays on sched­ule, and will mir­ror the Monts, France lo­ca­tion.

The Swedish CD­MO got the go-ahead to man­u­fac­ture Mod­er­na’s Covid-19 vac­cine af­ter ap­proval from the EMA’s Com­mit­tee for Hu­man Med­i­cine at the start of Ju­ly, and helped en­sure the time­ly de­liv­ery of Covid-19 vac­cines to Eu­rope.

As former synbio unicorn Zymergen picks up the pieces from its spectacular implosion Tuesday, an outstanding loan from Perceptive Advisors — the only blue-chip biotech crossover investor to touch Zymergen’s fundraising efforts — could make the situation worse, according to public documents.

In December 2019, more than a year before Zymergen filed for what would eventually become a $500 million IPO, the “biofacturing” firm signed a $100 million credit facility with Perceptive to help supplement the nearly $700 million the company had raised across four VC rounds.

What can $1 billion buy? If you’re Amgen, it’s good for two manufacturing facilities in the US.

The California-based drug giant will invest close to $550 million in a drug substance plant in Holly Springs, NC, adding itself to an ever-growing list of biotech companies that have decided to call North Carolina home, and marking its second drug manufacturing announcement in a little more than a month.